Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India
This article was originally published in PharmAsia News
Ranbaxy set to lose 180-day exclusivity on three products, potentially five more as it begins process to meet new requirements.
You may also be interested in...
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
Proposed rule would eliminate petitioner advantage when patent board is deciding whether to institute inter partes review of patent claims.
USPTO pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months. Prioritized examination is available solely for small entities and would save them $2,000.